Sign In

Login

Password

Forgot Password ? Sign Up

Tegaserod (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tegaserod" in German language version.

refsWebsite
Global rank German rank
3doi.org
2nd place
3rd place
3nih.gov
4th place
7th place
2web.archive.org
1st place
1st place
2redirecter.toolforge.org
33rd place
2nd place
2europa.eu
68th place
29th place
1fda.gov
447th place
751st place
1healthycanadians.gc.ca
low place
low place
1prnewswire.com
406th place
1,055th place
1pharmatimes.com
low place
low place
1cas.org
8,332nd place
1,213th place
1chemspider.com
8,573rd place
1,211th place
1drugbank.ca
4,294th place
2,006th place
1wikidata.org
43rd place
985th place

cas.org

commonchemistry.cas.org

chemspider.com

doi.org

  • S. Appel-Dingemanse: Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. In: Clinical Pharmacokinetics. Band 41, 2002, doi:10.2165/00003088-200241130-00002.
  • D T Beattie, J A M Smith, D Marquess, R G Vickery, S R Armstrong: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. In: British Journal of Pharmacology. Band 143, Nr. 5, November 2004, S. 549–560, doi:10.1038/sj.bjp.0705929, PMID 15466450, PMC 1575425 (freier Volltext).
  • Jeanne Loughlin, Sherry Quinn, Elena Rivero, Judy Wong, Jiaquing Huang: Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. In: Journal of Cardiovascular Pharmacology and Therapeutics. Band 15, Nr. 2, Juni 2010, S. 151–157, doi:10.1177/1074248409360357, PMID 20200325.

drugbank.ca

europa.eu

ema.europa.eu

echa.europa.eu

fda.gov

accessdata.fda.gov

healthycanadians.gc.ca

nih.gov

ncbi.nlm.nih.gov

  • D T Beattie, J A M Smith, D Marquess, R G Vickery, S R Armstrong: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. In: British Journal of Pharmacology. Band 143, Nr. 5, November 2004, S. 549–560, doi:10.1038/sj.bjp.0705929, PMID 15466450, PMC 1575425 (freier Volltext).
  • Jeanne Loughlin, Sherry Quinn, Elena Rivero, Judy Wong, Jiaquing Huang: Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. In: Journal of Cardiovascular Pharmacology and Therapeutics. Band 15, Nr. 2, Juni 2010, S. 151–157, doi:10.1177/1074248409360357, PMID 20200325.

pubchem.ncbi.nlm.nih.gov

pharmatimes.com

prnewswire.com

redirecter.toolforge.org

  • FDA approves first treatment for women with constipation-predominant irritable bowel syndrome. 5. Februar 2007, archiviert vom Original am 5. Februar 2007; abgerufen am 17. Februar 2021 (englisch).
  • Novartis suspends US marketing and sales of Zelnorm in response to request from FDA. 10. April 2007, archiviert vom Original (nicht mehr online verfügbar) am 10. April 2007; abgerufen am 14. Februar 2021 (englisch).

web.archive.org

  • FDA approves first treatment for women with constipation-predominant irritable bowel syndrome. 5. Februar 2007, archiviert vom Original am 5. Februar 2007; abgerufen am 17. Februar 2021 (englisch).
  • Novartis suspends US marketing and sales of Zelnorm in response to request from FDA. 10. April 2007, archiviert vom Original (nicht mehr online verfügbar) am 10. April 2007; abgerufen am 14. Februar 2021 (englisch).

wikidata.org